Provided by Tiger Trade Technology Pte. Ltd.

Neo-Concept International Group Holdings Limited

6.96
+1.0116.97%
Post-market: 7.000.0400+0.57%16:39 EST
Volume:16.07M
Turnover:104.04M
Market Cap:131.64M
PE:25.56
High:9.00
Open:5.74
Low:3.40
Close:5.95
52wk High:9.00
52wk Low:0.7200
Shares:18.91M
Float Shares:945.20K
Volume Ratio:2.30
T/O Rate:1699.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2723
EPS(LYR):0.2648
ROE:16.08%
ROA:6.19%
PB:17.69
PE(LYR):26.29

Loading ...

Neo-Concept International Grp Hldngs Ltd trading halted, volatility trading pause

TIPRANKS
·
Yesterday

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:31 AM

Reuters
·
Yesterday

Positive Report for NTG Clarity Networks (NCI) from Atrium Research

TIPRANKS
·
Feb 20

What's Going On With Neo-Concept International Stock Friday?

Benzinga_recent_news
·
Feb 14

Neo-Concept International Group Holdings Limited Announces Closing of Approximately US$8.1 Million Public Offering of Class A Ordinary Shares

GlobeNewswire
·
Feb 12

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:43 AM

Reuters
·
Feb 11

BRIEF-Neo-Concept International Group Holdings Announces Pricing Of Approximately $8.1 Mln Public Offering Of Class A Ordinary Shares

Reuters
·
Feb 10

Shell announces commencement of a share buyback programme

GlobeNewswire
·
Feb 05

Press Release: Shell plc Fourth Quarter 2025 Interim Dividend

Dow Jones
·
Feb 05

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

GlobeNewswire
·
Jan 28

Shell fourth quarter 2025 update note

GlobeNewswire
·
Jan 08

Neo-Concept International Appoints Pengfei Jiang to Board

Reuters
·
Dec 17, 2025

Neo-Concept International Group Holdings Limited (NASDAQ:NCI) Surges 45% Yet Its Low P/E Is No Reason For Excitement

Simply Wall St.
·
Dec 16, 2025

Press Release: SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

Dow Jones
·
Dec 08, 2025

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

GlobeNewswire
·
Dec 04, 2025

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire
·
Dec 01, 2025

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

GlobeNewswire
·
Nov 24, 2025

Neo-Concept International H1 EPS $0.06 Up From $0.05 YoY, Sales $7.674M Down From $10.150M YoY

Benzinga
·
Nov 21, 2025

Press Release: Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results

Dow Jones
·
Nov 21, 2025

National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations

prnewswire
·
Nov 21, 2025